ITM

Princeton,  NJ 
United States
https://www.itm-radiopharma.com

• Booth: 1001

ITM is a vertically integrated biotechnology company dedicated to delivering the promise of radiopharmaceuticals to patients. Over the last 20 years, we have developed our business to encompass every stage of the process: beginning with the production of radioisotopes and expanding to develop our own radiopharmaceuticals for diagnosis and treatment. We are also expanding our capabilities in the manufacture and supply of novel radioisotopes, and we are growing our ability to produce and supply new types of radioisotopes, advancing our position as a leading global supplier of n.c.a. Lutetium (Lu-177) and Actinium-225 (Ac-225).

Brands: GeGant Ga-68 Generators, EndolucinBeta n.c.a. Lu-177, iQS - Theranostics Synthesizer for Radiolabeling,

 Press Releases

• Positive Topline Results of Phase 3 COMPETE Trial (Mar 21, 2025)

  ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

  • Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimus
  • ITM plans to submit the COMPETE data for presentation at a future medical conference, with potential US regulatory submission anticipated in 2025
  • ITM continues to advance a broad clinical pipeline, with multiple assets being investigated across seven different tumor types, including glioblastoma and clear cell renal cell carcinoma